![Arndt Vogel: Impressive and comprehensive review on BRAF mutations](https://oncodaily.com/pub/uploads/2023/08/Arndt-Vogel-1-e1691671535612-1280x799.jpeg)
Photo of Arndt Vogel from journalonko.de
Feb 25, 2024, 15:01
Arndt Vogel: Impressive and comprehensive review on BRAF mutations
Arndt Vogel shared on X/Twitter:
“BRAF — a tumor-agnostic drug target with lineage-specific dependencies.
Impressive and comprehensive review on BRAF mutations:
- RAF inhibitor paradox,
- New combinations,
- Overcoming resistance.”
Proceed to the article.
Source: Arndt Vogel/X
Arndt Vogel is a managing senior consultant and professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. He is the Head of the GI-Cancer Center and of the Center for Personalized Medicine at Medical School Hannover and chairs the Hepatobiliary Cancer Study Group of the AIO, a collaborative group in clinical oncology in Germany. His scientific focus is translational and clinical research in gastrointestinal cancer.